Lead Compound

The Apogee of Therapeutic Innovation

ABC294640 has demonstrated excellent efficacy, safety and drug characteristics.  It is an orally available small molecule.  It has an excellent pharmacokinetic profile that is expected to translate into b.i.d. dosing.  ABC294640 has demonstrated efficacy in animal models of several solid tumor cancers as well as inflammation coupled with a GLP toxicology package that is unremarkable in regards to toxicities.

Due to the multiple cellular cascades it effects through SK inhibition, it has also shown good synergy with several current standard of care cancer therapeutics providing a rational for combination studies in upcoming clinical trials. It has a simple synthesis scheme and has been GMP manufactured inexpensively.  It has shown excellent fill, dissolution and stability characteristics for clinical capsule formulation and b.i.d. dosing.

A Phase I clinical trial in all solid tumors with expansion to pancreatic cancer is currently ongoing. This initial clinical trial is expected to provide the foundation and rationale for multiple Phase II clinical trials in various specific solid tumor cancers and inflammatory indications, based on results and funding availability.